ecallantide
Commercial- Indications
- Hereditary angioedema
Company intelligence / Profile preview
Dyax Corp.
Unknown, Massachusetts, United Statesdyax.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Dyax developed and commercialized KALBITOR (ecallantide) for HAE acute treatment in patients 12 years and older. Their lead candidate DX-2930 showed >90% reduction in HAE attacks compared to placebo in Phase 1B trials.
- Therapeutic areas
- HematologyRare Diseases
- Modalities
- Monoclonal antibodiesBiotherapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Genzyme Corporation (terminated 2007)Paul Capital PartnersEli Lilly & Co.
Beyond the preview
Go deeper on Dyax Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dyax Corp..